VIGAMOX™ (moxifloxacin HCl ophthalmic solution) 0.5% is a sterile ophthalmic solution. It is an 8-methoxy fluoroquinolone anti-infective for topical ophthalmic use.
VIGAMOX™ solution is indicated for the treatment of bacterial conjunctivitis caused by susceptible strains of the following organisms:
Aerobic Gram-positive microorganisms:
Corynebacterium species *
Micrococcus luteus *
Staphylococcus warneri *
Streptococcus viridans group
Aerobic Gram-negative microorganisms:
Acinetobacter lwoffii *
Haemophilus parainfluenzae *
*Efficacy for this organism was studied in fewer than 10 infections.
Media Articles Related to Vigamox (Moxifloxacin)
Moxifloxacin Struggles Against Current TB Drugs: REMox Trial
Source: Medscape HIV/AIDS Headlines [2014.09.07]
Although a shorter, moxifloxacin-containing regimen did not measure up to standard tuberculosis therapy, the drug shows promise, experts say.
Medscape Medical News
Published Studies Related to Vigamox (Moxifloxacin)
14-day bactericidal activity of PA-824, bedaquiline, pyrazinamide, and
moxifloxacin combinations: a randomised trial. 
first 14 days of treatment to assess their suitability for future development... INTERPRETATION: PA-824-moxifloxacin-pyrazinamide is potentially suitable for
Neither moxifloxacin nor cefuroxime produces significant attenuation of inflammatory mediator release in patients exposed to cardiopulmonary bypass: a randomized controlled trial. [2011.10.03]
OBJECTIVES: (i) the inflammatory response to CPB may be different from that of infectious disease states that were used to establish the immunomodulatory effects of moxifloxacin; and (ii) a single intravenous dose, which was used in this investigation, may not lead to high enough plasma and intracellular concentrations..
The use of beat-to-beat electrocardiogram analysis to distinguish QT/QTc interval changes caused by moxifloxacin from those caused by vardenafil. [2011.09]
QT correction factors (QTc) can cause errors in the interpretation of drug effects on cardiac repolarization because they do not adequately differentiate changes when heart rate or autonomic state deviates from the baseline QT/RR interval relationship... This study demonstrated that newer methods of electrocardiogram (ECG) analysis can differentiate changes in the QT interval to improve identification of proarrhythmia risk.
Human aqueous humor concentrations of besifloxacin, moxifloxacin, and gatifloxacin after topical ocular application. [2011.06]
PURPOSE: To determine the concentrations of besifloxacin, moxifloxacin, and gatifloxacin in human aqueous humor after topical instillation of commercially available besifloxacin ophthalmic suspension 0.6%, moxifloxacin ophthalmic solution 0.5%, and gatifloxacin ophthalmic solution 0.3%, and to assess these concentrations relative to the minimum inhibitory concentration for 90% of strains (MIC(90)) for each drug against bacterial pathogens identified in recent cases of postoperative endophthalmitis. SETTING: Six clinical sites, United States. DESIGN: Randomized open-label controlled clinical trial... CONCLUSIONS: Based on the aqueous humor drug concentrations measured in this study, it is unlikely that any of the fluoroquinolones tested would be therapeutically effective in the aqueous humor against the most frequently identified drug-resistant staphylococcal isolates from recent cases of postoperative endophthalmitis. FINANCIAL DISCLOSURE: No author has a financial or proprietary interest in any material or method mentioned. Additional disclosures are found in the footnotes. Copyright (c) 2011 ASCRS and ESCRS. Published by Elsevier Inc. All rights reserved.
Comparative efficacy and safety of moxifloxacin and clindamycin in the treatment of odontogenic abscesses and inflammatory infiltrates: a phase II, double-blind, randomized trial. [2011.03]
Moxifloxacin penetrates well into oromaxillary tissue and covers the causative pathogens that show an increasing resistance to standard antibiotics.No significant differences between groups were found for patients with odontogenic abscesses.
Clinical Trials Related to Vigamox (Moxifloxacin)
Intermittent Moxifloxacin Therapy For The Prevention Of Acute Exacerbations In Patients With Chronic Bronchitis [Completed]
Moxifloxacin, is being tested at approximately 60 study centres in 15 countries to determine
if this drug, when taken periodically in addition to the patients normal treatment, is
effective at reducing the number of flare-ups of chronic bronchitis he has. Approximately
1132 subjects will participate, and it is expected that the study will run for 2 years in
order to reach that goal. The patients individual involvement in the study will be 17
months. Moxifloxacin will be compared to a placebo drug (no active ingredients). The study
medication (moxifloxacin or placebo) will be taken in addition to the patients normal
medication for chronic bronchitis. In addition to the first clinic visit, called a screening
visit, the patient will be required to come back to the clinic for ten more study visits,
every 8 weeks. At the first visit the study co-ordinator will provide him with the dates for
all the visits. Over a period of 48 weeks the patient will return to the clinic on 6
occasions where he will receive the study medication which he will take for five days, in
addition to his normal treatment for chronic bronchitis. After this time the patient will
enter a follow up period for 24 weeks, where he will come to the clinic for assessments and
continue to take his normal medication but not receive the study drug. A complete medical
history will be taken at the first visit, including the patients past and current smoking
habit. A breath test will be performed to assess how well his lungs are functioning. In
addition, he will also be asked to provide a sputum sample for a microbiological examination
to identify any bacteria present in the sample. The patient must be able to provide a sputum
sample at the screening visit. If the patient meets all the inclusion / exclusion criteria
for the study, he will be allocated randomly to one of the following treatment groups at the
- Treatment group 1: Receives moxifloxacin orally once daily for five days.
- Treatment group 2: Receives a matching placebo once daily for five days. In between each
visit (four weeks after your clinic visit), the study site co-ordinator will contact the
patient to check on his well being. If the patient or the doctor decides to stop the
patients participation in the trial for any reason, the patient will be required to
return to the clinic for a physical examination, take a breath test, provide a sputum
sample (if possible) and have a blood sample taken.
TBTC Study 27/28 PK: Moxifloxacin Pharmacokinetics During TB Treatment [Completed]
This substudy of TBTC Studies 27 and 28 compares 1) the pharmacokinetics of moxifloxacin
alone versus moxifloxacin administered with rifampin in healthy volunteers and 2) the
pharmacokinetics of moxifloxacin among patients with tuberculosis being treated with
multidrug therapy (isoniazid or ethambutol, rifampin, and pyrazinamide) to those of healthy
volunteers receiving moxifloxacin plus rifampin. It also evaluates the association between
polymorphisms of MDR1 genotype (P-glycoprotein) and rifampin pharmacokinetic parameters, the
effect of polymorphisms of MDR1 genotype and/or rifampin pharmacokinetics on isoniazid
pharmacokinetic parameters adjusted for N-acetyltransferase genotype (NAT2), and determines
by multivariate regression analyses the associations between moxifloxacin or rifampin
pharmacokinetic parameters and markers of tuberculosis disease severity including the
covariates of two-month culture positivity, cavitary lung disease, Body Mass Index, weight,
duration of study treatment prior to PK, co-morbidities and C-reactive protein. Healthy
volunteers and TB patients receive frequent scheduled blood draws during a 24 hour period
after ingesting a dose of TB drugs.
TBTC Study 28: Moxifloxacin Versus Isoniazid for TB Treatment [Active, not recruiting]
This double-blind, randomized controlled trial evaluates moxifloxacin versus isoniazid in
daily treatment during the first two months of treatment with rifampin, pyrazinamide and
ethambutol for sputum smear-positive pulmonary tuberculosis.
Controlled Comparison of Two Moxifloxacin Containing Treatment Shortening Regimens in Pulmonary Tuberculosis [Recruiting]
REMoxTB is a study for the "Rapid Evaluation of Moxifloxacin in the treatment of sputum
smear positive tuberculosis". REMoxTB aims to find and evaluate new drugs and regimens that
shorten the duration of tuberculosis therapy.
The purpose of REMoxTB is to evaluate the efficacy, safety and acceptability of two
moxifloxacin-containing treatment combinations to determine whether substituting ethambutol
with moxifloxacin in one combination, and/or substituting isoniazid with moxifloxacin in
another combination, makes it possible to reduce the duration of treatment for TB.
Efficacy and Safety of Sequential IV/PO Moxifloxacin in Comparison to IV Levofloxacin Plus IV Ceftriaxone Followed by PO Levofloxacin, in the Treatment of Patients With Community-Acquired Pneumonia [Completed]
Sequential therapy with intravenous to oral moxifloxacin, was tested at 69 study centres in
17 countries to determine if this treatment regimen is safe and effective in treating
hospitalized adult patients with community-acquired pneumonia. 748 patients were participated
in the study over an 18 months period. Individual patient involvement in the study was
approximately 4-6 weeks. Moxifloxacin was compared to a combination treatment regimen of high
dose intravenous ceftriaxone plus high dose intravenous levofloxacin followed by high dose
Reports of Suspected Vigamox (Moxifloxacin) Side Effects
Toxic Anterior Segment Syndrome (85),
OFF Label USE (31),
Eye Pain (21),
Visual Acuity Reduced (17),
Medication Error (16),
Eye Irritation (10),
Retinal Detachment (10),
Post Procedural Complication (8), more >>
PATIENT REVIEWS / RATINGS / COMMENTS
Based on a total of 1 ratings/reviews, Vigamox has an overall score of 10. The effectiveness score is 10 and the side effect score is 10. The scores are on ten point scale: 10 - best, 1 - worst.
Vigamox review by 27 year old female patient
|Overall rating:|| || |
|Effectiveness:|| || Highly Effective|
|Side effects:|| || No Side Effects|
|Condition / reason:|| || conjunctivitus|
|Dosage & duration:|| || 2-3 drops (dosage frequency: 2-3 x a day) for the period of 5 days|
|Other conditions:|| || n/a|
|Other drugs taken:|| || n/a|
|Benefits:|| || The rx cleared up my conjunctivitus. It was fast & easy to use. I was surpised @ how quickly it worked. It does sting when you use but on the other hand as soon as the pink eye goes away it doesnt sting anymore.|
|Side effects:|| || It stings a little & you can't wear contacts until its over.|
|Comments:|| || you get a 3 ml eye drop bottle & use 1-2 drops 2-3 x a day until it goes away. I still have half a bottle left.|
Page last updated: 2014-09-07